Novartis AG revised earnings guidance for the year 2024. For the year, net sales now expected to grow high single to low double-digit compared to the previous guidance of from mid-single-digit and core operating income now expected to grow low double-digit to mid-teens compared to the previous guidance of from high single-digit.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93.37 CHF | +0.81% | +1.14% | +10.02% |
May. 16 | Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 | DP |
May. 16 | Novartis: presents results of tender offer for MorphoSysy | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.02% | 209B | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+8.49% | 169B | |
-0.52% | 164B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis AG Revise Earnings Guidance for the Year 2024